

Organon reaches settlement in case involving Mircette

Arnhem, the Netherlands, December 2, 2005 – Akzo Nobel's human healthcare business, Organon, has reached a settlement in a court case concerning a generic version of Organon's Mircette® oral contraceptive.

The agreement terminates a patent litigation involving Duramed Pharmaceuticals, Inc., a subsidiary of Barr Pharmaceuticals, Inc.

Barr has agreed to pay Organon USD 139 million for the settlement of the patent litigation and the acquisition of all rights relating to Mircette, including the U.S. marketing approval.

- - -

Note for the editor

Akzo Nobel (EURONEXT: AKZ; NASDAQ: AKZOY), based in the Netherlands, serves customers throughout the world with healthcare products, coatings and chemicals. Listed on both the Euronext and NASDAQ Stock Exchanges, the company is a member of the Dow Jones Sustainability Index. Consolidated revenues for 2004 totaled EUR 12.7 billion. The Company currently employs some 62,000 people in more than 80 countries. The financial results for 2005 will be published on February 7, 2006.

About Organon

Organon is the human health care business unit of Akzo Nobel and creates, manufactures and markets prescription medicines that improve the health and quality of human life. Through a combination of independent growth and business partnerships, Organon strives to remain or become one of the leading pharmaceutical companies in each of its core therapeutic fields: reproductive medicine, psychiatry and anesthesia. Organon products are sold in over 100 countries, of which more than 60 have an Organon subsidiary.

About Barr

Barr Pharmaceuticals, Inc., is a holding company, whose principal subsidiaries, Barr Laboratories, Inc. and Duramed Pharmaceuticals, Inc., develop, manufacture and market generic and proprietary pharmaceuticals. A research-intensive pharmaceutical company, Barr currently manufactures and markets more than 100 different dosage forms and strengths of over 70 different generic pharmaceutical products, including 22 oral contraceptive products, representing the largest category of the Company's generic portfolio, and 17 proprietary pharmaceutical products, largely concentrated in the female healthcare arena.

Internet:

www.akzonobel.com; www.organon.com; www.barrlabs.com

Not for publication – for more information

Akzo Nobel N.V.
Corporate Media Relations, tel. +31 26 366 4343
Contact: Tim van der Zanden